Medicilon Supports Jemincare's JMX-2002 Liposome Injection Clinical Trial Approval

Shanghai, China – October 16, 2024 – Medicilon is pleased to announce that its long-term partner, Jemincare Group Co., Ltd. ("Jemincare"), has received clinical trial approval from the China National Medical Products Administration (NMPA) for its innovative liposome injection drug, JMX-2002, for the treatment of solid tumors, including non-small cell lung cancer and breast cancer.

JMX-2002: A New Hope for Solid Tumor Treatment

JMX-2002 Liposome Injection is designed to enhance drug targeting and bioavailability while minimizing damage to healthy tissues. Using liposomes as drug carriers, this novel formulation improves the delivery and effectiveness of treatment for solid tumors, offering a promising alternative to traditional therapies with fewer side effects. The approval marks a significant milestone in liposome-based drug development and provides cancer patients with a new therapeutic option.

Medicilon’s Role in Liposome Drug Development

Medicilon has been instrumental in advancing JMX-2002’s development, providing comprehensive preclinical support through its specialized liposome drug development platform. This platform covers lipid synthesis, liposome preparation, formulation screening, safety evaluation, pharmacokinetics, and regulatory support, helping to optimize the drug’s efficacy and safety profile.

Congratulations to Jemincare

Medicilon congratulates Jemincare on this achievement and looks forward to the continued progress of JMX-2002 through clinical trials. We remain committed to advancing drug development in partnership with global leaders to bring innovative treatments to clinical practice.

About Jemincare

Founded in 1999, Jemincare Group Co., Ltd. ("Jemincare") is a leading health industry group based in Nanchang, China, dedicated to innovation in pharmaceuticals and health solutions.

About ShanHe Pharmaceutical

Wuxi JiYu ShanHe Pharmaceutical Co., Ltd. ("ShanHe Pharmaceutical"), founded in 1956, specializes in both Chinese and Western medicine, with a focus on high-tech pharmaceutical research and production.

About JinYuan Pharmaceutical

Changzhou JinYuan Pharmaceutical Manufacturing Co., Ltd. ("JinYuan Pharmaceutical"), founded in 1993, is a leading enterprise in liposome-based oncology drug research and industrialization in China.

About Medicilon

Founded in 2004, Medicilon (Stock Code: 688202.SH) provides comprehensive preclinical drug research services for global pharmaceutical companies and institutions. With over 2,000 clients and 490 IND-approved drugs, Medicilon accelerates drug development through efficient project management and innovative solutions.